A major milestone in pancreatic cancer treatment: Daraxonrasib is now FDA approved for certain patients with metastatic pancreatic cancer after clinical trial results nearly doubled median overall survival compared with chemotherapy.
Hear from Diane M. Simeone, MD, Director of
